Prevention and management of venous thromboembolism in people with cancer: A review of the evidence

Clinical Oncology

Volumn 18, Issue 2, 2006, Pages 145-151

  Cunningham, Moya S ^a   White, B ^a   O'Donnell, J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cancer; Primary thromboprophylaxis; Secondary thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CISPLATIN; CYCLOSPORIN; DALTEPARIN; ENOXAPARIN; ESTROGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TACROLIMUS; TAMOXIFEN; THALIDOMIDE; TINZAPARIN; WARFARIN;

BLEEDING DISORDER; CANCER PATIENT; CANCER SURVIVAL; CENTRAL VENOUS CATHETER; CLINICAL STUDY; CLINICAL TRIAL; COMPRESSION THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEVELOPING COUNTRY; DIARRHEA; DISEASE EXACERBATION; DRUG COST; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; LIVER DISEASE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MANAGED CARE; META ANALYSIS; METASTASIS; ONCOLOGY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 31644450523     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.10.001     Document Type: Article

References (72)

1. E. Oger Incidence of venous thromboembolism: A community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale Thromb Haemost 83 2000 657-660
2. H. Partsch K. Oburger A. Mostbeck et al. Frequency of pulmonary embolism in ambulant patients with pelvic vein thrombosis: A prospective study J Vasc Surg 16 1992 715-722
3. C. Kearon Natural history of venous thromboembolism Circulation 107 2003 I22-I30
4. W.H. Geerts G.F. Pineo J.A. Heit et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 338S-400S
5. Committee HoCH. The prevention of venous thromboembolism in hospitalised patients, 2005.
6. M. Gidiri M. Sant K. Philips et al. Thromboprophylaxis for caesarean section: How can uptake and coverage be improved? J Obstet Gynaecol 24 2004 392-394
7. K. Deep M.V. Jigajinni M.H. Fraser et al. Prophylaxis of thromboembolism in spinal injuries: Survey of practice in spinal units in the British Isles Injury 33 2002 353-355
8. G. Wright K. Elliott C. Wilkie et al. A prospective audit of hospital-acquired deep vein thrombosis and pulmonary embolism Int J Clin Pract 53 1999 497-504
9. N. Levitan A. Dowlati S.C. Remick et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285-291
10. J.A. Heit M.D. Silverstein D.N. Mohr et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study Arch Intern Med 160 2000 809-815
11. J.A. Heit W.M. O'Fallon T.M. Petterson et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study Arch Intern Med 162 2002 1245-1248
12. H.T. Sorensen L. Mellemkjaer J.H. Olsen et al. Prognosis of cancers associated with venous thromboembolism N Engl J Med 343 2000 1846-1850
13. F.A. Anderson Jr. F.A. Spencer Risk factors for venous thromboembolism Circulation 107 2003 9-16
14. D.A. Lane P.M. Mannucci K.A. Bauer et al. Inherited thrombophilia: Part 2 Thromb Haemost 76 1996 824-834
15. D.A. Lane P.M. Mannucci K.A. Bauer et al. Inherited thrombophilia: Part 1 Thromb Haemost 76 1996 651-662
16. P. Prandoni A. Piccioli A. Girolami Cancer and venous thromboembolism: an overview Haematologica 84 1999 437-445
17. N. Goldenberg S.R. Kahn S. Solymoss Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism J Clin Oncol 21 2003 4194-4199
18. V.S. Shen E.W. Pollak Fatal pulmonary embolism in cancer patients: Is heparin prophylaxis justified? South Med J 73 1980 841-843
19. P. Prandoni A.W. Lensing A. Piccioli et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484-3488
20. O. Huber H. Bounameaux F. Borst et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk Arch Surg 127 1992 310-313
21. W.H. Geerts J.A. Heit G.P. Clagett et al. Prevention of venous thromboembolism Chest 119 2001 132S-175S
22. G.P. Clagett J.S. Reisch Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis Ann Surg 208 1988 227-240
23. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group Br J Surg 84 1997 1099-1103
24. D. Bergqvist U.S. Burmark P.A. Flordal et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients Br J Surg 82 1995 496-501
25. D. Bergqvist G. Agnelli A.T. Cohen et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 2002 975-980
26. M.S. Rasmussen Preventing thromboembolic complications in cancer patients after surgery: A role for prolonged thromboprophylaxis Cancer Treat Rev 28 2002 141-144
27. O.E. Dahl T. Aspelin H. Arnesen et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery Thromb Res 80 1995 299-306
28. H. Galster G. Kolb A. Kohsytorz et al. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups Thromb Res 100 2000 381-388
29. A.Y. Lee Management of thrombosis in cancer: Primary prevention and secondary prophylaxis Br J Haematol 128 2005 291-302
30. B. Fisher J. Costantino C. Redmond et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 320 1989 479-484
31. K.I. Pritchard A.H. Paterson N.A. Paul et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group J Clin Oncol 14 1996 2731-2737
32. M.A. Elliott R.C. Wolf C.C. Hook et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with l -asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin Leuk Lymphoma 45 2004 1545-1549
33. M. Zangari E. Anaissie B. Barlogie et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 2001 1614-1615
34. M. Levine J. Hirsh M. Gent et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer Lancet 343 1994 886-889
35. R.D. Bona Thrombotic complications of central venous catheters in cancer patients Semin Thromb Hemost 25 1999 147-155
36. L.J. Walshe S.F. Malak J. Eagan et al. Complication rates among cancer patients with peripherally inserted central catheters J Clin Oncol 20 2002 3276-3281
37. M.M. Bern J.J. Lokich S.R. Wallach et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial Ann Intern Med 112 1990 423-428
38. D.C. Heaton D.Y. Han A. Inder Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis Intern Med J 32 2002 84-88
39. M. Monreal A. Alastrue M. Rull et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices: Prophylaxis with a low molecular weight heparin (Fragmin) Thromb Haemost 75 1996 251-253
40. Anonymous Collaborative overview of randomised trials of antiplatelet therapy: III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration BMJ 308 1994 235-246
41. R. McKenna J. Galante F. Bachmann et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression BMJ 280 1980 514-517
42. Anonymous Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial Lancet 355 2000 1295-1302
43. M. Gent J. Hirsh J.S. Ginsberg et al. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture Circulation 93 1996 80-84
44. S.V. Amaragiri L.T. Lees Elastic compression stockings for prevention of deep vein thrombosis The Cochrane Library, Issue 2 2001 John Wiley & Sons Ltd Chichester, UK
45. A.J. Comerota M.L. Katz J.V. White Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg 164 1992 265-268
46. F.S. Haddad R.M. Kerry J.A. McEwen et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: A possible source of variation in reported patient outcomes J Arthroplasty 16 2001 37-46
47. P.S. Wells J. Hirsh D.R. Anderson et al. Accuracy of clinical assessment of deep-vein thrombosis Lancet 345 1995 1326-1330
48. P.S. Wells D.R. Anderson J. Bormanis et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management Lancet 350 1997 1795-1798
49. P.S. Wells D.R. Anderson M. Rodger et al. Evaluation of d -dimer in the diagnosis of suspected deep-vein thrombosis N Engl J Med 349 2003 1227-1235
50. W.K. Ho G.J. Hankey C.H. Lee et al. Venous thromboembolism: Diagnosis and management of deep venous thrombosis Med J Aust 182 2005 476-481
51. T.E. Warkentin M.N. Levine J. Hirsh et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330-1335
52. A.J. Palmer W. Schramm B. Kirchhof et al. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: A meta-analysis of randomised clinical trials Haemostasis 27 1997 65-74
53. P. Mismetti S. Laporte J.Y. Darmon et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery Br J Surg 88 2001 913-930
54. M.M. Koopman P. Prandoni F. Piovella et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group N Engl J Med 334 1996 682-687
55. M. Levine M. Gent J. Hirsh et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis N Engl J Med 334 1996 677-681
56. B.A. Hutten M.H. Prins M. Gent et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis J Clin Oncol 18 2000 3078-3083
57. G. Palareti C. Legnani A. Lee et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy Thromb Haemost 84 2000 805-810
58. A.Y. Lee M.N. Levine R.I. Baker et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146-153
59. S.R. Deitcher G. Merli J. Rigas R.M. Lyons S. Cort Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: A randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period [abstract] J Thromb Haemost 1 2003 OC194
60. R.D. Hull G.F. Pineo C. Francis et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison. North American Fragmin Trial Investigators Arch Intern Med 160 2000 2208-2215
61. S.I. Noble I.G. Finlay Is long-term low-molecular weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study Palliat Med 19 2005 197-201
62. D. Aujesky K.J. Smith J. Cornuz M.S. Roberts Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism Chest 128 2005 1601-1610
63. H. Decousus A. Leizorovicz F. Parent et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group N Engl J Med 338 1998 409-415
64. D. Green R.D. Hull R. Brant et al. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin Lancet 339 1992 1476
65. M.K. Gould A.D. Dembitzer R.L. Doyle et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials Ann Intern Med 130 1999 800-809
66. A.K. Kakkar M.N. Levine Z. Kadziola et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 2004 1944-1948
67. M. Altinbas H.S. Coskun O. Er et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 2004 1266-1271
68. C.P. Klerk S.M. Smorenburg H.M. Otten et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 2005 2130-2135
69. A.Y. Lee F.R. Rickles J.A. Julian et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism J Clin Oncol 23 2005 2123-2129
70. N.R. Lemoine Antithrombotic therapy in cancer J Clin Oncol 23 2005 2119-2120
71. A. Falanga The effect of anticoagulant drugs on cancer J Thromb Haemost 2 2004 1263-1265
72. S.M. Smorenburg R.J. Hettiarachchi R. Vink et al. The effects of unfractionated heparin on survival in patients with malignancy - a systematic review Thromb Haemost 82 1999 1600-1604